Search

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration is now open

OverviewThe EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus…

Read more

Addressing the bureaucracy challenge

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research.

Read more

What an EHA Kick-off Grant supports

Our EHA Kick-off Grant supports basic and translational lab-based research in hematology. Costs that can be supported by an EHA Kick-off Grant
Lab consumables. Max € 5,000 for equipment, if properly justified.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Stem Cells

Mission:

The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.

Read more

A journey to hematology – a dream come true

YoungEHA proudly presents our first blog authored by a guest writer, Dr. Ana Zelić Kerep, a resident physician in the Department of Hematology, University Hospital Center Zagreb, Croatia. A journey to hematology – a dream come true

by Dr.

Read more

La Cantera coaching

Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more